Confidential Materials omitted and filed separately with the Securities and Exchange Commission. Double asterisks denote omissions.Strategic Alliance and Option • May 15th, 2017 • Editas Medicine, Inc. • Biological products, (no disgnostic substances) • New York
This STRATEGIC ALLIANCE AND OPTION AGREEMENT (the “Agreement”) is entered into and made effective as of March 14, 2017 (the “Effective Date”) by and between Editas Medicine, Inc., a Delaware corporation (“Editas”) and Allergan Pharmaceuticals International Limited, a public company limited by shares organized under the laws of Ireland (“Allergan”). Editas and Allergan are each referred to herein by name or as a “Party” or, collectively, as “Parties.”
